

# Delpazolid

Catalog No: tcsc0018175



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1219707-39-7

**Formula:**

$C_{14}H_{17}FN_4O_3$

**Pathway:**

Anti-infection

**Target:**

Bacterial

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 30 mg/mL (97.30 mM; Need ultrasonic and warming)

**Alternative Names:**

LCB01-0371

### Observed Molecular Weight:

308.31


## Product Description

Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of **MSSA** and **MRSA** with a **MIC<sub>90</sub>** of 2 µg/mL for both of them.

IC50 & Target: MIC90: 2 µg/mL (MSSA), 2 µg/mL (MRSA)<sup>[1]</sup>

**In Vitro:** Delpazolid (LCB01-0371), at concentrations of 1×MIC and 2×MIC, has bacteriostatic activity against MSSA and MRSA after 24 h. At concentrations of 4×MIC and 8×MIC, Delpazolid shows bacteriostatic activity, but there is no regrowth at concentrations of 4×MIC and 8×MIC after 24 h of incubation<sup>[1]</sup>. The survival of *M. abscessus* is greatly decreased in the presence of Delpazolid (LCB-0371) (MIC<sub>50</sub>=1.2 µg/mL). Delpazolid dramatically decreases the number of intracellular mycobacteria present at 2 days after infection at concentrations of 0.1, 1, and 10 µg/mL<sup>[2]</sup>.

**In Vivo:** When administered orally, Delpazolid (LCB01-0371) shows potent protective effects against systemic infections caused by Gram-positive and Gram-negative bacteria. Against infection caused by *S. aureus* Giorgio (MSSA), the ED<sub>50</sub> of Delpazolid is 4.53 mg/kg of body weight. Against *S. aureus* p125 (MRSA), the ED<sub>50</sub> of Delpazolid is 2.96 mg/kg<sup>[1]</sup>. When Delpazolid (LCB-0371) is administered at 100 mg/kg daily (by gavage), the colony-forming unit (CFU) counts tend to be decreased in the lungs of mice at 7 days after infection<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!